Key points: Venetoclax combined with Obinutuzumab was superior to Obinutuzumab plus Chlorambucil across different genetic subgroups, but 17p deletion and mutated TP53 remain as adverse prognostic markers. Unmutated IGHV is a predictive factor for particular benefit from Venetoclax and Obinutuzumab. (Abstract only)
Home / Resource Library / Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax